Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma

Donald W Coulter, Angela D. Boettner, Zbigniew P. Kortylewicz, Stephen P. Enke, Jake A. Luther, Vivek Verma, Janina Baranowska-Kortylewicz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Blood-based biomarkers are important in the detection of the disease and in the assessment of responses to therapy. In this study, butyrylcholinesterase was evaluated as a potential biomarker in newly diagnosed neuroblastoma (NB) patients at diagnosis and longitudinally during treatment. Plasma butyrylcholinesterase activities in age-matched and sex-matched children were used as controls. Pretreatment butyrylcholinesterase levels in NB subjects are on an average 2 times lower than butyrylcholinesterase levels in healthy subjects. Significantly, butyrylcholinesterase activities are ∼40% lower in MYCN-amplified as compared with nonamplified disease. As the course of chemotherapy progresses, butyrylcholinesterase activities recover and normalize to control values. The evident response to treatment indicates that plasma butyrylcholinesterase is a good biomarker of tumor response to therapy. Depressed butyrylcholinesterase levels in NB subjects are not caused by hepatic deficits suggesting a specific role for butyrylcholinesterase in NB. Further examination of the mechanism of altered butyrylcholinesterase production require an animal model that best approximates human condition. Studies in mice show that murine NB allografts significantly reduce butyrylcholinesterase activity in plasma. This finding correlates with changes observed in NB patients. In contrast, human NB xenografts produce the opposite effect, that is, butyrylcholinesterase plasma levels rise as the xenograft size increases. In the absence of any liver damage, dissimilarities between butyrylcholinesterase production in murine and human NB models suggest species-specific signaling pathways. This disparity also suggests that human NB xenograft mouse models do not approximate the human disease.

Original languageEnglish (US)
Pages (from-to)272-281
Number of pages10
JournalJournal of Pediatric Hematology/Oncology
Volume39
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Butyrylcholinesterase
Neuroblastoma
Biomarkers
Heterografts
Liver
Therapeutics
Tumor Biomarkers
Allografts

Keywords

  • blood biomarker
  • butyrylcholinesterase
  • neuroblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma. / Coulter, Donald W; Boettner, Angela D.; Kortylewicz, Zbigniew P.; Enke, Stephen P.; Luther, Jake A.; Verma, Vivek; Baranowska-Kortylewicz, Janina.

In: Journal of Pediatric Hematology/Oncology, Vol. 39, No. 4, 01.01.2017, p. 272-281.

Research output: Contribution to journalArticle

Coulter, Donald W ; Boettner, Angela D. ; Kortylewicz, Zbigniew P. ; Enke, Stephen P. ; Luther, Jake A. ; Verma, Vivek ; Baranowska-Kortylewicz, Janina. / Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma. In: Journal of Pediatric Hematology/Oncology. 2017 ; Vol. 39, No. 4. pp. 272-281.
@article{e288eea91e294f90bda428ab18161cb4,
title = "Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma",
abstract = "Blood-based biomarkers are important in the detection of the disease and in the assessment of responses to therapy. In this study, butyrylcholinesterase was evaluated as a potential biomarker in newly diagnosed neuroblastoma (NB) patients at diagnosis and longitudinally during treatment. Plasma butyrylcholinesterase activities in age-matched and sex-matched children were used as controls. Pretreatment butyrylcholinesterase levels in NB subjects are on an average 2 times lower than butyrylcholinesterase levels in healthy subjects. Significantly, butyrylcholinesterase activities are ∼40{\%} lower in MYCN-amplified as compared with nonamplified disease. As the course of chemotherapy progresses, butyrylcholinesterase activities recover and normalize to control values. The evident response to treatment indicates that plasma butyrylcholinesterase is a good biomarker of tumor response to therapy. Depressed butyrylcholinesterase levels in NB subjects are not caused by hepatic deficits suggesting a specific role for butyrylcholinesterase in NB. Further examination of the mechanism of altered butyrylcholinesterase production require an animal model that best approximates human condition. Studies in mice show that murine NB allografts significantly reduce butyrylcholinesterase activity in plasma. This finding correlates with changes observed in NB patients. In contrast, human NB xenografts produce the opposite effect, that is, butyrylcholinesterase plasma levels rise as the xenograft size increases. In the absence of any liver damage, dissimilarities between butyrylcholinesterase production in murine and human NB models suggest species-specific signaling pathways. This disparity also suggests that human NB xenograft mouse models do not approximate the human disease.",
keywords = "blood biomarker, butyrylcholinesterase, neuroblastoma",
author = "Coulter, {Donald W} and Boettner, {Angela D.} and Kortylewicz, {Zbigniew P.} and Enke, {Stephen P.} and Luther, {Jake A.} and Vivek Verma and Janina Baranowska-Kortylewicz",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MPH.0000000000000828",
language = "English (US)",
volume = "39",
pages = "272--281",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma

AU - Coulter, Donald W

AU - Boettner, Angela D.

AU - Kortylewicz, Zbigniew P.

AU - Enke, Stephen P.

AU - Luther, Jake A.

AU - Verma, Vivek

AU - Baranowska-Kortylewicz, Janina

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Blood-based biomarkers are important in the detection of the disease and in the assessment of responses to therapy. In this study, butyrylcholinesterase was evaluated as a potential biomarker in newly diagnosed neuroblastoma (NB) patients at diagnosis and longitudinally during treatment. Plasma butyrylcholinesterase activities in age-matched and sex-matched children were used as controls. Pretreatment butyrylcholinesterase levels in NB subjects are on an average 2 times lower than butyrylcholinesterase levels in healthy subjects. Significantly, butyrylcholinesterase activities are ∼40% lower in MYCN-amplified as compared with nonamplified disease. As the course of chemotherapy progresses, butyrylcholinesterase activities recover and normalize to control values. The evident response to treatment indicates that plasma butyrylcholinesterase is a good biomarker of tumor response to therapy. Depressed butyrylcholinesterase levels in NB subjects are not caused by hepatic deficits suggesting a specific role for butyrylcholinesterase in NB. Further examination of the mechanism of altered butyrylcholinesterase production require an animal model that best approximates human condition. Studies in mice show that murine NB allografts significantly reduce butyrylcholinesterase activity in plasma. This finding correlates with changes observed in NB patients. In contrast, human NB xenografts produce the opposite effect, that is, butyrylcholinesterase plasma levels rise as the xenograft size increases. In the absence of any liver damage, dissimilarities between butyrylcholinesterase production in murine and human NB models suggest species-specific signaling pathways. This disparity also suggests that human NB xenograft mouse models do not approximate the human disease.

AB - Blood-based biomarkers are important in the detection of the disease and in the assessment of responses to therapy. In this study, butyrylcholinesterase was evaluated as a potential biomarker in newly diagnosed neuroblastoma (NB) patients at diagnosis and longitudinally during treatment. Plasma butyrylcholinesterase activities in age-matched and sex-matched children were used as controls. Pretreatment butyrylcholinesterase levels in NB subjects are on an average 2 times lower than butyrylcholinesterase levels in healthy subjects. Significantly, butyrylcholinesterase activities are ∼40% lower in MYCN-amplified as compared with nonamplified disease. As the course of chemotherapy progresses, butyrylcholinesterase activities recover and normalize to control values. The evident response to treatment indicates that plasma butyrylcholinesterase is a good biomarker of tumor response to therapy. Depressed butyrylcholinesterase levels in NB subjects are not caused by hepatic deficits suggesting a specific role for butyrylcholinesterase in NB. Further examination of the mechanism of altered butyrylcholinesterase production require an animal model that best approximates human condition. Studies in mice show that murine NB allografts significantly reduce butyrylcholinesterase activity in plasma. This finding correlates with changes observed in NB patients. In contrast, human NB xenografts produce the opposite effect, that is, butyrylcholinesterase plasma levels rise as the xenograft size increases. In the absence of any liver damage, dissimilarities between butyrylcholinesterase production in murine and human NB models suggest species-specific signaling pathways. This disparity also suggests that human NB xenograft mouse models do not approximate the human disease.

KW - blood biomarker

KW - butyrylcholinesterase

KW - neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=85017175704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017175704&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000828

DO - 10.1097/MPH.0000000000000828

M3 - Article

C2 - 28375942

AN - SCOPUS:85017175704

VL - 39

SP - 272

EP - 281

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -